Hey jobo. If you go to research/valuation thread and look at @ma420 post, Wilson's does a brief comparison to pluvicto, and specifically assess cohort 2 and 3 without cohort 1, which was most likely underdosing.
Ann: Theranostic prostate cancer trial advances to multi-dose, page-33
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.07 |
Change
-0.020(0.49%) |
Mkt cap ! $1.265B | |||
| Open | High | Low | Value | Volume |
| $4.10 | $4.12 | $3.96 | $2.286M | 570.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 2616 | $4.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.07 | 5368 | 5 |
View Market Depth
| Last trade - 13.34pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.07 |
Change
-0.020 ( 0.62 %) |
||||
| Open | High | Low | Volume | ||
| $4.12 | $4.12 | $3.96 | 29193 | ||
| Last updated 14.09pm 22/05/2024 ? | |||||
| CU6 (ASX) Chart |